2024

• Bawa, Z., Lewis, D., Gavin, P., Libinaki, R., Joubran, L., El-Tamimy, M., Taylor, G., Meltzer, R., Bedoya-Perez, M., Kevin, R., McGregor, I. (2024). An open-label feasibility trial of transdermal cannabidiol for hand osteoarthritis. Scientific Reports, 14(1). [More Information]
• Suraev, A., McCartney, D., Kevin, R., Gordon, R., Grunstein, R., Hoyos, C., McGregor, I. (2024). Detection of Δ9-tetrahydrocannabinol (THC) in oral fluid using two point-of-collection testing devices following oral administration of a THC and cannabidiol containing oil. Drug Testing and Analysis. [More Information]
• Bawa, Z., McCartney, D., Bedoya-Perez, M., Lau, N., Fox, R., MacDougall, H., McGregor, I. (2024). Effects of cannabidiol on psychosocial stress, situational anxiety and nausea in a virtual reality environment: a protocol for a single-centre randomised clinical trial. BMJ Open, 14(3). [More Information]
• Suraev, A., Hoyos, C., McGregor, I., McCartney, D., Marshall, N., Irwin, C., Vandrey, R., Grunstein, R., D’Rozario, A., Gordon, C., et al (2024). Evaluating possible ‘next day’ impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial. Psychopharmacology. [More Information]
• Mills, L., Arnold, J., Suraev, A., Abelev, S., Zhou, C., Arkell, T., McGregor, I., Lintzeris, N. (2024). Medical cannabis use in Australia seven years after legalisation: findings from the online Cannabis as Medicine Survey 2022–2023 (CAMS-22). Harm Reduction Journal, 21(1). [More Information]
• Sparkes, E., Maloney, C., Markham, J., Dane, C., Boyd, R., Gilchrist, J., Moir, M., Gordon, R., Luo, J., Pike, E., Walker, K., Kassiou, M., McGregor, I., Kevin, R., Hibbs, D., Jorgensen, W., Banister, S., Cairns, E., Ametovski, A. (2024). Structure-Activity Relationships, Deuteration, and Fluorination of Synthetic Cannabinoid Receptor Agonists Related to AKB48, 5F-AKB-48, and AFUBIATA. ACS Chemical Neuroscience, 15(11), 2160-2181. [More Information]
• McCartney, D., McGregor, I., Irwin, C., Bawa, Z., Palmer, B., Sahinovic, A., Delang, N., Cox, G., Desbrow, B., Lau, N. (2024). The Effect of Cannabidiol on Subjective Responses to Endurance Exercise: A Randomised Controlled Trial. SPORTS MEDICINE-OPEN, 10(1), 61. [More Information]
• Hurzeler, T., Logge, W., Watt, J., DeMayo, M., Suraev, A., McGregor, I., Haber, P., Morley, K. (2024). The neurobehavioural effects of cannabidiol in alcohol use disorder: Study protocol for a double-blind, randomised, cross over, placebo-controlled trial. Contemporary Clinical Trials Communications, 41, 101341. [More Information]

2023

• Milligan, C., Anderson, L., McGregor, I., Arnold, J., Petrou, S. (2023). Beyond CBD: Inhibitory effects of lesser studied phytocannabinoids on human voltage-gated sodium channels. Frontiers in Physiology, 14. [More Information]
• Lavender, I., McCartney, D., Marshall, N., Suraev, A., Irwin, C., D'Rozario, A., Gordon, C., Saini, B., Grunstein, R., Yee, B., McGregor, I., et al (2023). Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. BMJ Open, 13(8), e071148. [More Information]
• Arkell, T., Abelev, S., Mills, L., Suraev, A., Arnold, J., Lintzeris, N., McGregor, I. (2023). Driving-related behaviors, attitudes, and perceptions among Australian medical cannabis users: results from the CAMS 20 survey. Journal of Cannabis Research, 5(1). [More Information]
• McCartney, D., Kevin, R., Suraev, A., Sahinovic, A., Doohan, P., Bedoya-Perez, M., Grunstein, R., Hoyos, C., McGregor, I. (2023). How long does a single oral dose of cannabidiol persist in plasma? Findings from three clinical trials. Drug Testing and Analysis, 15(3), 334-344. [More Information]
• Suraev, A., Mills, L., Abelev, S., Arkell, T., McGregor, I., Lintzeris, N. (2023). Medical Cannabis Use Patterns for Sleep Disorders in Australia: Results of the Cross-Sectional CAMS-20 Survey. Nature and Science of Sleep, 15, 245-255. [More Information]
• Cairns, E., Benson, M., Bedoya-Perez, M., MacPhail, S., Mohan, A., Cohen, R., Sachdev, P., McGregor, I. (2023). Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing. Frontiers in Pharmacology, 14. [More Information]
• Harman, T., Udoh, M., McElroy, D., Anderson, L., Kevin, R., Banister, S., Ametovski, A., Markham, J., Bladen, C., Doohan, P., McGregor, I., Arnold, J., et al (2023). MEPIRAPIM-derived synthetic cannabinoids inhibit T-type calcium channels with divergent effects on seizures in rodent models of epilepsy. Frontiers in Physiology, 14. [More Information]
• Rodan, S., Bryant, E., Le, A., Maloney, D., Touyz, S., McGregor, I., Maguire, S. (2023). Pharmacotherapy, alternative and adjunctive therapies for eating disorders: findings from a rapid review. Journal of Eating Disorders, 11(1). [More Information]
• McCartney, D., Suraev, A., McGregor, I. (2023). The ""Next Day"" Effects of Cannabis Use: A Systematic Review. Cannabis and Cannabinoid Research, 8(1), 92-114. [More Information]
• Delang, N., Irwin, C., Peek, A., McGregor, I., Desbrow, B., McCartney, D. (2023). The effect of contact/collision sport participation without concussion on neurometabolites: A systematic review and meta-analysis of magnetic resonance spectroscopy studies. Journal of Neurochemistry, 167(5), 615-632. [More Information]
• Arnold, J., McCartney, D., Suraev, A., McGregor, I. (2023). The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence. Clinical and Translational Science, 16(1), 1930-10-01 00:00:00. [More Information]

2022

• Bawa, Z., Saini, B., McCartney, D., Bedoya-Perez, M., McLachlan, A., McGregor, I. (2022). A cross-sectional survey exploring the knowledge, experiences and attitudes of Australian pharmacists toward medicinal cannabis. International Journal of Clinical Pharmacy. [More Information]
• Milligan, C., Anderson, L., Bowen, M., Banister, S., McGregor, I., Arnold, J., Petrou, S. (2022). A nutraceutical product, extracted from Cannabis sativa, modulates voltage-gated sodium channel function. Journal of Cannabis Research, 4(1). [More Information]
• Colvin, E., Hudson, A., Anderson, L., Kumar, R., McGregor, I., Howell, V., Arnold, J. (2022). An Examination of the Anti-Cancer Properties of Plant Cannabinoids in Preclinical Models of Mesothelioma. Cancers, 14(15). [More Information]
• McCartney, D., Arkell, T., Irwin, C., Kevin, R., McGregor, I. (2022). Are blood and oral fluid ?9-tetrahydrocannabinol (THC) and metabolite concentrations related to impairment? A meta-regression analysis. Neuroscience and Biobehavioral Reviews, 134, 104433. [More Information]
• Umpierrez, L., Costa, P., Michelutti, E., Baracz, S., Sauer, M., Turner, A., Everett, N., Arnold, J., McGregor, I., Cornish, J. (2022). Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses. Psychopharmacology, 239(5), 1593-1603. [More Information]
• Amminger, G., Lin, A., Kerr, M., Weller, A., Spark, J., Pugh, C., O'Callaghan, S., Berger, M., Clark, S., Scott, J., McGregor, I., et al (2022). Cannabidiol for at risk for psychosis youth: A randomized controlled trial. Early Intervention in Psychiatry, 16(4), 419-432. [More Information]
• Berger, M., Li, E., Rice, S., Davey, C., Ratheesh, A., Adams, S., Jackson, H., Hetrick, S., Parker, A., Spelman, T., Kevin, R., McGregor, I., et al (2022). Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial. Journal of Clinical Psychiatry, 83(5). [More Information]
• Lavender, I., McGregor, I., Suraev, A., Grunstein, R., Hoyos, C. (2022). Cannabinoids, Insomnia, and Other Sleep Disorders. Chest, 162(2), 452-465. [More Information]
• Hutten, N., Arkell, T., Vinckenbosch, F., Schepers, J., Kevin, R., Theunissen, E., Kuypers, K., McGregor, I., Ramaekers, J. (2022). Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis. Psychopharmacology, 239(11), 3731-3741. [More Information]
• Mills, L., Dunlop, A., Montebello, M., Copeland, J., Bruno, R., Jefferies, M., McGregor, I., Lintzeris, N. (2022). Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder. Substance Abuse Treatment, Prevention, and Policy, 17(1). [More Information]
• Markham, J., Sparkes, E., Boyd, R., Chen, S., Manning, J., Finlay, D., Lai, F., McGregor, E., Maloney, C., Gerona, R., McGregor, I., Hibbs, D., Kevin, R., Banister, S., et al (2022). Defining Steric Requirements at CB1 and CB2 Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues. ACS Chemical Neuroscience, 13(8), 1281-1295. [More Information]
• Suraev, A., Benson, M., Martin, L., Lintzeris, N., McGregor, I. (2022). Determination of contaminants in artisanal cannabis products used for childhood epilepsy in the Australian community: A sub-analysis of the ‘PELICAN’ study. Epilepsy and Behavior, 127, 1-5. [More Information]
• Sahinovic, A., Irwin, C., Doohan, P., Kevin, R., Cox, A., Lau, N., Desbrow, B., Johnson, N., Sabag, A., Hislop, M., Haber, P., McGregor, I., McCartney, D. (2022). Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial. SPORTS MEDICINE-OPEN, 8(1), 27. [More Information]
• McCartney, D., Suraev, A., Doohan, P., Irwin, C., Kevin, R., Grunstein, R., Hoyos, C., McGregor, I. (2022). Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial. Journal of Psychopharmacology, 36(12), 1338-1349. [More Information]
• Benson, M., Anderson, L., Low, I., Luo, J., Kevin, R., Zhou, C., McGregor, I., Arnold, J. (2022). Evaluation of the Possible Anticonvulsant Effect of Δ⁹-Tetrahydrocannabinolic Acid in Murine Seizure Models. Cannabis and Cannabinoid Research, 7(1), 46-57. [More Information]
• Mirlohi, S., Bladen, C., Santiago, M., Arnold, J., McGregor, I., Connor, M. (2022). Inhibition of human recombinant T-type calcium channels by phytocannabinoids in vitro. British Journal of Pharmacology, 179(15), 4031-4043. [More Information]
• Bawa, Z., McCartney, D., Manocha, R., McGregor, I. (2022). Knowledge, experiences, and attitudes of Australian General Practitioners towards medicinal cannabis: a 2021–2022 survey. BMC Primary Care, 23(1). [More Information]
• Lintzeris, N., Mills, L., Abelev, S., Suraev, A., Arnold, J., McGregor, I. (2022). Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20). Harm Reduction Journal, 19(1). [More Information]
• Berger, M., Amminger, G., McGregor, I. (2022). Medicinal cannabis for the treatment of anxiety disorders. Australian Journal of General Practice, 51(8), 586-592. [More Information]
• MacPhail, S., Bedoya-Perez, M., Cohen, R., Kotsirilos, V., McGregor, I., Cairns, E. (2022). Medicinal Cannabis Prescribing in Australia: An Analysis of Trends Over the First Five Years. Frontiers in Pharmacology, 13. [More Information]
• Montebello, M., Jefferies, M., Mills, L., Bruno, R., Copeland, J., McGregor, I., Rivas, C., Jackson, M., Silsbury, C., Dunlop, A., Lintzeris, N. (2022). Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial. Drug and Alcohol Dependence, 234, 109388-1-109388-8. [More Information]
• Kevin, R., Cairns, E., Boyd, R., Arnold, J., Bowen, M., McGregor, I., Banister, S. (2022). Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11. Frontiers in Psychiatry, 13. [More Information]
• Anderson, L., Udoh, M., Everett-Morgan, D., Heblinski, M., McGregor, I., Banister, S., Arnold, J. (2022). Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. Journal of Cannabis Research, 4(1). [More Information]
• McCartney, D., Kevin, R., Suraev, A., Irwin, C., Grunstein, R., Hoyos, C., McGregor, I. (2022). Orally administered cannabidiol does not produce false-positive tests for triangle 9-tetrahydrocannabinol on the Securetec DrugWipe® 5S or Drager DrugTest® 5000. Drug Testing and Analysis, 14(1), 137-143. [More Information]
• Baracz, S., Robinson, K., Wright, A., Turner, A., McGregor, I., Cornish, J., Everett, N. (2022). Oxytocin as an adolescent treatment for methamphetamine addiction after early life stress in male and female rats. Neuropsychopharmacology, 47(8), 1561-1573. [More Information]
• Mills, L., Lintzeris, N., O'Malley, M., Arnold, J., McGregor, I. (2022). Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition. Drug and Alcohol Review, 41(5), 1095-1108. [More Information]
• Kevin, R., Mirlohi, S., Manning, J., Boyd, R., Cairns, E., Ametovski, A., Lai, F., Luo, J., Jorgensen, W., Ellison, R., Hibbs, D., McGregor, I., Banister, S., et al (2022). Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (CaV3) Inhibitors. ACS Chemical Neuroscience, 13(9), 1395-1409. [More Information]
• Arkell, T., Kevin, R., Vinckenbosch, F., Lintzeris, N., Theunissen, E., Ramaekers, J., McGregor, I. (2022). Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials. Addiction Biology, 27(2), e13125. [More Information]
• Reis, A., Hammond, J., Stevanovski, I., Arnold, J., McGregor, I., Deveson, I., Gururajan, A. (2022). Sex-specific transcriptomic and epitranscriptomic signatures of PTSD-like fear acquisition. iScience, 25(9). [More Information]
• Sparkes, E., Cairns, E., Kevin, R., Lai, F., Grafinger, K., Chen, S., Deventer, M., Ellison, R., Boyd, R., Martin, L., McGregor, I., Hibbs, D., Banister, S., et al (2022). Structure-activity relationships of valine, tert -leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. RSC Medicinal Chemistry, 13(2), 156-174. [More Information]
• Sparkes, E., Boyd, R., Chen, S., Markham, J., Luo, J., Foyzun, T., Zaman, H., Fletcher, C., Ellison, R., McGregor, I., Lai, F., Hibbs, D., Cairns, E., Ametovski, A., Banister, S., et al (2022). Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA, MDMB-4F-BUTINACA and their analogs. Frontiers in Psychiatry, 13. [More Information]
• Udoh, M., Bladen, C., Heblinski, M., Luo, J., Satpute Janve, V., Anderson, L., McGregor, I., Arnold, J. (2022). The anticonvulsant phytocannabinoids CBGVA and CBDVA inhibit recombinant T-type channels. Frontiers in Pharmacology, 13. [More Information]

2021

• Kevin, R., Vogel, R., Doohan, P., Berger, M., Amminger, G., McGregor, I. (2021). A validated method for the simultaneous quantification of cannabidiol, Δ9‐tetrahydrocannabinol, and their metabolites in human plasma and application to plasma samples from an oral cannabidiol open‐label trial. Drug Testing and Analysis, 13(3), 614-627. [More Information]
• Bedoya-Perez, M., Le, A., McGregor, I., Crowther, M. (2021). Antipredator responses toward cat fur in wild brown rats tested in a semi-natural environment. Behavioral Ecology, 32(5), 835-844. [More Information]
• Martin, L., Cairns, E., Heblinski, M., Fletcher, C., Krycer, J., Arnold, J., McGregor, I., Bowen, M., Anderson, L. (2021). Cannabichromene and Δ9-Tetrahydrocannabinolic Acid Identified as Lactate Dehydrogenase-A Inhibitors by in Silico and in Vitro Screening. Journal of Natural Products, 84(5), 1469-1472. [More Information]
• Anderson, L., Ametovski, A., Luo, J., Everett-Morgan, D., McGregor, I., Banister, S., Arnold, J. (2021). Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome. ACS Chemical Neuroscience, 12(2), 330-339. [More Information]
• Anderson, L., Heblinski, M., Absalom, N., Hawkins, N., Bowen, M., Benson, M., Zhang, F., Bahceci, D., Doohan, P., Collins, M., McGregor, I., Arnold, J., et al (2021). Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. British Journal of Pharmacology, 178(24), 4826-4841. [More Information]
• Anderson, L., Doohan, P., Oldfield, L., Kevin, R., Arnold, J., Berger, M., Amminger, P., McGregor, I. (2021). Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. Journal of Clinical Psychopharmacology, 41(5), 525-533. [More Information]
• McCartney, D., Arkell, T., Irwin, C., McGregor, I. (2021). Determining the magnitude and duration of acute Δ⁹-tetrahydrocannabinol (Δ⁹-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review. Neuroscience and Biobehavioral Reviews, 126, 175-193. [More Information]
• Ramaekers, J., Arkell, T., McGregor, I. (2021). Driving Impairment following Vaporization of Cannabis - Reply. JAMA - Journal of the American Medical Association, 325(12), 1226-1227. [More Information]
• Arkell, T., McCartney, D., McGregor, I. (2021). Medical cannabis and driving. Australian Journal of General Practice, 50(6), 357-362. [More Information]
• Perkins, D., Brophy, H., McGregor, I., O'Brien, P., Quilter, J., McNamara, L., Sarris, J., Stevenson, M., Gleeson, P., Sinclair, J., et al (2021). Medicinal cannabis and driving: the intersection of health and road safety policy. International Journal of Drug Policy, 97, 103307. [More Information]
• Ametovski, A., Cairns, E., Grafinger, K., Cannaert, A., Deventer, M., Chen, S., Wu, X., Shepperson, C., Lai, F., Ellison, R., Kevin, R., McGregor, I., Hibbs, D., Banister, S., et al (2021). NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity? ACS Chemical Neuroscience, 12(21), 4020-4036. [More Information]
• Rodan, S., Aouad, P., McGregor, I., Maguire, S. (2021). Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa. OBM Neurobiology, 5(2). [More Information]
• Devenish, S., Winters, B., Anderson, L., Arnold, J., McGregor, I., Vaughan, C., Collins, M., Absalom, N. (2021). The anticonvulsant zonisamide positively modulates recombinant and native glycine receptors at clinically relevant concentrations. Neuropharmacology, 182. [More Information]
• Bedoya-Perez, M., Ward, M., Loomes, M., McGregor, I., Crowther, M. (2021). The efect of COVID19 pandemic restrictions on an urban rodent population. Scientific Reports, 11(1), Article number 12957-1-Article number 12957-14. [More Information]
• McCartney, D., Isik, A., Rooney, K., Arnold, J., Bartlett, D., Murnion, B., Richards, E., Arkell, T., Lintzeris, N., McGregor, I. (2021). The effect of daily aerobic cycling exercise on sleep quality during inpatient cannabis withdrawal: A randomised controlled trial. Journal of Sleep Research, 30, 1-12. [More Information]
• Arkell, T., Spindle, T., Kevin, R., Vandrey, R., McGregor, I. (2021). The failings of per se limits to detect cannabis-induced driving impairment: Results from a simulated driving study. Traffic Injury Prevention, 22(2), 102-107. [More Information]
• Jackson, M., Brown, A., Johnston, J., Clancy, R., McGregor, I., Bruno, R., Lintzeris, N., Montebello, M., Luksza, J., Bowman, J., Allsop, D., et al (2021). The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients. Journal of Cannabis Research, 3(1), 33. [More Information]

2020

• McGregor, I., Cairns, E., Abelev, S., Cohen, R., Henderson, M., Couch, D., Arnold, J., Gauld, N. (2020). Access to cannabidiol without a prescription: A cross-country comparison and analysis. International Journal of Drug Policy, 85, 102935. [More Information]
• Benson, M., Abelev, S., Corte, C., Connor, S., McGregor, I. (2020). Attitudes and knowledge of australian gastroenterologists around the use of medicinal cannabis for inflammatory bowel disease. Crohn's & Colitis 360, 2(2), 1-9. [More Information]
• Suraev, A., Grunstein, R., Marshall, N., D'Rozario, A., Gordon, C., Bartlett, D., Wong, K., Yee, B., Vandrey, R., Irwin, C., Arnold, J., McGregor, I., Hoyos, C. (2020). Cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) for chronic insomnia disorder ('CANSLEEP' trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. BMJ Open, 10(5), e034421. [More Information]
• McCartney, D., Benson, M., Desbrow, B., Irwin, C., Suraev, A., McGregor, I. (2020). Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research. Sports Medicine - Open, 6(1), 27. [More Information]
• Suraev, A., Marshall, N., Vandrey, R., McCartney, D., Benson, M., McGregor, I., Grunstein, R., Hoyos, C. (2020). Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. Sleep Medicine Reviews, 53, 1-16. [More Information]
• Lintzeris, N., Mills, L., Dunlop, A., Copeland, J., McGregor, I., Bruno, R., Kirby, A., Montebello, M., Hall, M., Jefferies, M., Kevin, R., Bhardwaj, A. (2020). Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. Drug and Alcohol Dependence, 215, 108220. [More Information]
• Arkell, T., Lintzeris, N., Mills, L., Suraev, A., Arnold, J., McGregor, I. (2020). Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 Survey. Accident Analysis and Prevention, 148, 105784. [More Information]
• Arkell, T., Vinckenbosch, F., Kevin, R., Theunissen, E., McGregor, I., Ramaekers, J. (2020). Effect of Cannabidiol and Δ⁹-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial. JAMA, 324(21), 2177-2186. [More Information]
• Absalom, N., Liao, V., Kothur, K., Indurthi Venkata, D., Bennetts, B., Troedson, C., Mohammad, S., Gupta, S., McGregor, I., Bowen, M., Ahring, J., Collins, M., et al (2020). Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies. Brain Communications, 2(2), fcaa162. [More Information]
• Gamage, T., Barrus, D., Kevin, R., Finlay, D., Lefever, T., Patel, P., Grabenauer, M., Glass, M., McGregor, I., Wiley, J., et al (2020). In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018. Pharmacology, Biochemistry and Behavior, 193, 1-12. [More Information]
• Anderson, L., Low, I., McGregor, I., Arnold, J. (2020). Interactions between cannabidiol and delta-9�]tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome. British Journal of Pharmacology, 177(18), 4261-4274. [More Information]
• Lintzeris, N., Mills, L., Suraev, A., Bravo, M., Arkell, T., Arnold, J., Benson, M., McGregor, I. (2020). Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduction Journal, 17(1), 37. [More Information]
• Benson, M., Abelev, S., Connor, S., Corte, C., Martin, L., Gold, L., Suraev, A., McGregor, I. (2020). Medicinal Cannabis for Inflammatory Bowel Disease: A Survey of Perspectives, Experiences, and Current Use in Australian Patients. Crohn's & Colitis 360, 2(2), otaa015. [More Information]
• Grimison, P., Mersiades, T., Kirby, A., Lintzeris, N., Morton, R., Haber, P., Olver, I., Walsh, A., McGregor, I., Cheung, Y., Simes, R., Stockler, M., et al (2020). Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Annals of Oncology, 31(11), 1553-1560. [More Information]
• Arnold, J., Nation, T., McGregor, I. (2020). Prescribing medicinal cannabis. Australian Prescriber, 43(5), 152-159. [More Information]
• Heblinski, M., Santiago, M., Fletcher, C., Stuart, J., Connor, M., McGregor, I., Arnold, J. (2020). Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Actions of Phytocannabinoids or Endocannabinoids on TRPA1 and TRPV1 Channels. Cannabis and Cannabinoid Research, 5(4), 305-317. [More Information]
• McCartney, D., Benson, M., Suraev, A., Irwin, C., Arkell, T., Grunstein, R., Hoyos, C., McGregor, I. (2020). The effect of cannabidiol on simulated car driving performance: A randomised, double�]blind, placebo�]controlled, crossover, dose�]ranging clinical trial protocol. Human Psychopharmacology: Clinical and Experimental, 35(5), e2749. [More Information]
• McGregor, I., Kassiou, M., Bowen, M., Hicks, C., Jorgensen, W. (2020). Novel small molecules that target social impairment and addictions (SOC 1). Patent No. 2715384. Russian Federation.

2019

• Santiago, M., Sachdev, S., Arnold, J., McGregor, I., Connor, M. (2019). Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of 9-THC at Human CB1 and CB2 Receptors. Cannabis and Cannabinoid Research, 4(3), 165-176. [More Information]
• Udoh, M., Santiago, M., Devenish, S., McGregor, I., Connor, M. (2019). Cannabichromene is a cannabinoid CB2 receptor agonist. British Journal of Pharmacology, 176(23), 4537-4547. [More Information]
• Arkell, T., Lintzeris, N., Kevin, R., Ramaekers, J., Vandrey, R., Irwin, C., Haber, P., McGregor, I. (2019). Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology, 236(9), 2713-2724. [More Information]
• Anderson, L., Absalom, N., Abelev, S., Low, I., Doohan, P., Martin, L., Chebib, M., McGregor, I., Arnold, J. (2019). Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia, 60(11), 2224-2234. [More Information]
• Kevin, R., Anderson, L., McGregor, I., Boyd, R., Manning, J., Glass, M., Connor, M., Banister, S. (2019). CUMYL-4CN-BINACA is an efficacious and potent pro-convulsant synthetic cannabinoid receptor agonist. Frontiers in Pharmacology, 10(595), 1-9. [More Information]
• Banister, S., Arnold, J., Connor, M., Glass, M., McGregor, I. (2019). Dark classics in chemical neuroscience: delta9-tetrahydrocannabinol. ACS Chemical Neuroscience, 10(5), 2160-2175. [More Information]
• Arkell, T., Kevin, R., Stuart, J., Lintzeris, N., Haber, P., Ramaekers, J., McGregor, I. (2019). Detection of Delta-9 THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devices. Drug Testing and Analysis, 11(10), 1486-1497. [More Information]
• Too, L., Yau, B., Baxter, A., McGregor, I., Hunt, N. (2019). Double deficiency of toll-like receptors 2 and 4 alters long-term neurological sequelae in mice cured of pneumococcal meningitis. Scientific Reports, 9(1), 1-13. [More Information]
• Absalom, N., Ahring, J., Liao, V., Balle, T., Jiang, T., Anderson, L., Arnold, J., McGregor, I., Bowen, M., Chebib, M. (2019). Functional genomics of epilepsy-associated mutations in the GABAa receptor subunits reveal that one mutation impairs function and two are catastrophic. Journal of Biological Chemistry, 294(15), 6157-6171. [More Information]
• Lintzeris, N., Bhardwaj, A., Mills, L., Dunlop, A., Copeland, J., McGregor, I., Bruno, R., Gugusheff, J., Phung, N., Montebello, M., Kirby, A., Allsop, D., et al (2019). Nabiximols for the Treatment of Cannabis Dependence A Randomized Clinical Trial. JAMA Internal Medicine, 179(9), 1242-1253. [More Information]
• Bedoya-Perez, M., Smith, K., Kevin, R., Luo, J., Crowther, M., McGregor, I. (2019). Parameters That Affect Fear Responses in Rodents and How to Use Them for Management. Frontiers in Ecology and Evolution, 7, 1-16. [More Information]
• Anderson, L., Low, I., Banister, S., McGregor, I., Arnold, J. (2019). Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome. Journal of Natural Products, 82(11), 3047-3055. [More Information]
• Banister, S., Adams, A., Kevin, R., MacDonald, C., Glass, M., Boyd, R., Connor, M., McGregor, I., Havel, C., Bright, S., et al (2019). Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. Drug Testing and Analysis, 11(2), 279-291. [More Information]
• Gamage, T., Farquhar, C., McKinnie, R., Kevin, R., McGregor, I., Trudell, M., Wiley, J., Thomas, B. (2019). Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors. Journal of Pharmacology and Experimental Therapeutics, 368(3), 414-422. [More Information]
• Banister, S., Kevin, R., Martin, L., Adams, A., MacDonald, C., Manning, J., Boyd, R., Cunningham, M., Stevens, M., McGregor, I., et al (2019). The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs. Drug Testing and Analysis, 11(7), 976-989. [More Information]
• Kevin, R., Kovach, A., Lefever, T., Gamage, T., Wiley, J., McGregor, I., Thomas, B. (2019). Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures. Forensic Toxicology, 37(1), 17-26. [More Information]

2018

• Suraev, A., Lintzeris, N., Stuart, J., Kevin, R., Blackburn, R., Richards, E., Arnold, J., Ireland, C., Todd, L., Allsop, D., McGregor, I. (2018). Author Correction: Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. Scientific Reports, 8(1), 1-1. [More Information]
• Parsons, M., Apfelbach, R., Banks, P., Cameron, E., Dickman, C., Frank, A., Jones, M., McGregor, I., McLean, S., Muller-Schwarze, D., et al (2018). Biologically meaningful scents: a framework for understanding predator-prey research across disciplines. Biological Reviews, 93(1), 98-114. [More Information]
• Hay, G., Baracz, S., Everett, N., Roberts, J., Costa, P., Arnold, J., McGregor, I., Cornish, J. (2018). Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats. Journal of Psychopharmacology, 32(12), 1369-1378. [More Information]
• McGregor, I. (2018). Cannabis use and non-cancer chronic pain. The Lancet Public Health, 3(10), e467. [More Information]
• Lovell, M., Bruno, R., Johnston, J., Matthews, A., McGregor, I., Allsop, D., Lintzeris, N. (2018). Cognitive, physical, and mental health outcomes between long-term cannabis and tobacco users. Addictive Behaviors, 79, 178-188. [More Information]
• Suraev, A., Lintzeris, N., Stuart, J., Kevin, R., Blackburn, R., Richards, E., Arnold, J., Ireland, C., Todd, L., Allsop, D., McGregor, I. (2018). Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. Scientific Reports, 8(1), 28127. [More Information]
• Bleeker, A., Crowther, M., Darke, S., Lintzeris, N., McGregor, I. (2018). David J. Allsop (7.12.1974-2013.8.2018). Drug and Alcohol Review, 37(7), 922-923. [More Information]
• Russell, J., Maguire, S., Hunt, G., Kesby, A., Suraev, A., Stuart, J., Booth, J., McGregor, I. (2018). Intranasal oxytocin in the treatment of anorexia nervosa: Randomized controlled trial during re-feeding. Psychoneuroendocrinology, 87, 83-92. [More Information]
• Kevin, R., Lefever, T., Snyder, R., Patel, P., Gamage, T., Fennell, T., Wiley, J., McGregor, I., Thomas, B. (2018). Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18. Drug Testing and Analysis, 10(1), 137-147. [More Information]
• Karanges, E., Suraev, A., Elias, N., Manocha, R., McGregor, I. (2018). Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey. BMJ Open, 8(7), 1-9. [More Information]
• Lintzeris, N., Driels, J., Elias, N., Arnold, J., McGregor, I., Allsop, D. (2018). Medicinal cannabis in Australia, 2016: the Cannabis as Medicine Survey (CAMS-16). Medical Journal of Australia, 209(5), 211-216. [More Information]
• Gamage, T., Farquhar, C., Lefever, T., Marusich, J., Kevin, R., McGregor, I., Wiley, J., Thomas, B. (2018). Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA. Journal of Pharmacology and Experimental Therapeutics, 365(2), 437-446. [More Information]
• Mersiades, T., Tognela, A., Haber, P., Stockler, M., Lintzeris, N., Simes, R., McGregor, I., Olver, I., Allsop, D., Gedye, C., Kirby, A., Morton, R., Wong, N., Walsh, A., Grimison, P., et al (2018). Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). BMJ Open, 8(9), 1-8. [More Information]
• Bhardwaj, A., Allsop, D., Copeland, J., McGregor, I., Dunlop, A., Shanahan, M., Bruno, R., Phung, N., Montebello, M., Sadler, C., Gugusheff, J., Lintzeris, N., et al (2018). Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol. BMC Psychiatry, 18(1), 1-14. [More Information]
• Banister, S., Olson, A., Winchester, M., Stuart, J., Edington, A., Kevin, R., Longworth, M., Herrera, M., Connor, M., McGregor, I., Kassiou, M., et al (2018). The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs. Drug Testing and Analysis, 10(7), 1099-1109. [More Information]
• Everett, N., McGregor, I., Baracz, S., Cornish, J. (2018). The role of the vasopressin V1A receptor in oxytocin modulation of methamphetamine primed reinstatement. Neuropharmacology, 133, 1-11. [More Information]

2017

• Kevin, R., Wood, K., Stuart, J., Mitchell, A., Moir, M., Banister, S., Kassiou, M., McGregor, I. (2017). Acute and residual effects in adolescent rats resulting rrom exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. Journal of Psychopharmacology, 31(6), 757-769. [More Information]
• Suraev, A., Todd, L., Bowen, M., Allsop, D., McGregor, I., Ireland, C., Lintzeris, N. (2017). An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use. Epilepsy and Behavior, 70, 334-340. [More Information]
• Clarke, D., Stuart, J., McGregor, I., Arnold, J. (2017). Endocannabinoid dysregulation in cognitive and stress-related brain regions in the Nrg1 mouse model of schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 72, 9-15. [More Information]
• Kevin, R., Lefever, T., Snyder, R., Patel, P., Fennell, T., Wiley, J., McGregor, I., Thomas, B. (2017). In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA. Forensic Toxicology, 35(2), 333-347. [More Information]
• Jorgensen, W., Bowen, M., McGregor, I., Werry, E., Reekie, T., Kassiou, M. (2017). Small molecule treatments for mental illness. Patent No. International PCT WO2017004674 A1, International PCT/AU2017/051371.
• Peters, S., Bowen, M., Bohrer, K., McGregor, I., Neumann, I. (2017). Oxytocin inhibits ethanol consumption and ethanol-induced dopamine release in the nucleus accumbens. Addiction Biology, 22(3), 702-711. [More Information]
• Longworth, M., Banister, S., Boyd, R., Kevin, R., Connor, M., McGregor, I., Kassiou, M. (2017). Pharmacology of cumyl-carboxamide synthetic cannabinoid new psychoactive substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and their analogues. ACS Chemical Neuroscience, 8(10), 2159-2167. [More Information]
• Allsop, D., Rooney, K., Arnold, J., Bhardwaj, A., Brunu, R., Bartlett, D., Montebello, M., Arkell, T., Richards, E., Gugusheff, J., Rooke, S., Kerley, W., Murnion, B., Haber, P., McGregor, I., Lintzeris, N. (2017). Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol. Mental Health and Physical Activity, 13, 57-67. [More Information]
• Bakas, T., van Nieuwenhuijzen, P., Devenish, S., McGregor, I., Arnold, J., Collins, M. (2017). The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors. Pharmacological Research, 119, 358-370. [More Information]
• Kevin, R., Allsop, D., Lintzeris, N., Dunlop, A., Booth, J., McGregor, I. (2017). Urinary cannabinoid levels during nabiximols (Sativex)-medicated inpatient cannabis withdrawal. Forensic Toxicology, 35(1), 33-44. [More Information]

2016

• Jones, M., Apfelbach, R., Banks, P., Cameron, E., Dickman, C., Frank, A., McLean, S., McGregor, I., Muller-Schwarze, D., Parsons, M., et al (2016). A Nose for Death: Integrating Trophic and Informational Networks for Conservation and Management. Frontiers in Ecology and the Environment, 4, 1-9. [More Information]
• Brzozowska, N., Li, K., Wang, X., Booth, J., Stuart, J., McGregor, I., Arnold, J. (2016). ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. PeerJ, 4(5), 1-17. [More Information]
• Hicks, C., Cornish, J., Baracz, S., Suraev, A., McGregor, I. (2016). Adolescent pre-treatment with oxytocin protects against adult methamphetamine-seeking behavior in female rats. Addiction Biology, 21(2), 304-315. [More Information]
• Too, L., McGregor, I., Baxter, A., Hunt, N. (2016). Altered behaviour and cognitive function following combined deletion of Toll-like receptors 2 and 4 in mice. Behavioural Brain Research, 303, 1-8. [More Information]
• Too, L., Mitchell, A., McGregor, I., Hunt, N. (2016). Antibody-induced neutrophil depletion prior to the onset of pneumococcal meningitis influences long-term neurological complications in mice. Brain, Behavior, and Immunity, 56, 68-83. [More Information]
• Too, L., Li, K., Suarna, C., Maghzal, G., Stocker, R., McGregor, I., Hunt, N. (2016). Behavioral and cognitive data in mice with different tryptophan-metabolizing enzymes knocked out. Data in Brief, 9, 275-287. [More Information]
• Baracz, S., Parker, L., Suraev, A., Everett, N., Goodchild, A., McGregor, I., Cornish, J. (2016). Chronic Methamphetamine Self-Administration Dysregulates Oxytocin Plasma Levels and Oxytocin Receptor Fibre Density in the Nucleus Accumbens Core and Subthalamic Nucleus of the Rat. Journal of Neuroendocrinology, 28(4), 1-13. [More Information]
• Luckett, T., Phillips, J., Lintzeris, N., Allsop, D., Lee, J., Solowij, N., Martin, J., Lam, L., Aggarwal, R., McCaffrey, N., Lovell, M., McGregor, I., et al (2016). Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: A survey of preferences, attitudes and beliefs among patients willing to consider participation. Internal Medicine Journal, 46(11), 1269-1275. [More Information]
• Karanges, E., Ramos, L., Dampney, B., Suraev, A., Li, K., McGregor, I., Hunt, G. (2016). Contrasting regional Fos expression in adolescent and young adult rats following acute administration of the antidepressant paroxetine. Brain Research Bulletin, 121, 246-254. [More Information]
• Monds, L., Paterson, H., Ali, S., Kemp, R., Bryant, R., McGregor, I. (2016). Cortisol response and psychological distress predict susceptibility to false memories for a trauma film. Memory, 24(9), 1278-1286. [More Information]
• Too, L., Li, K., Suarna, C., Maghzal, G., Stocker, R., McGregor, I., Hunt, N. (2016). Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive function. Behavioural Brain Research, 312, 102-117. [More Information]
• Arnold, J., Allsop, D., Lintzeris, N., McGregor, I. (2016). Evidence Check: Pharmacological actions and associated therapeutic levels of phytocannabinoids, (pp. 1 - 81). Sydney, Australia: The Sax Institute.
• Ramos, L., Hicks, C., Caminer, A., Couto, K., Narlawar, R., Kassiou, M., McGregor, I. (2016). MDMA ('Ecstasy'), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors. Pharmacology, Biochemistry and Behavior, 150-151, 115-123. [More Information]
• Kashem, M., Ahmed, S., Sultana, N., Ahmed, E., Pickford, R., Rae, C., Sery, O., McGregor, I., Balcar, V. (2016). Metabolomics of Neurotransmitters and Related Metabolites in Post-Mortem Tissue from the Dorsal and Ventral Striatum of Alcoholic Human Brain. Neurochemical Research, 41(1-2), 385-397. [More Information]
• Baracz, S., Everett, N., McGregor, I., Cornish, J. (2016). Oxytocin in the nucleus accumbens core reduces reinstatement of methamphetamine-seeking behaviour in rats. Addiction Biology, 21(2), 316-325. [More Information]
• Banister, S., Longworth, M., Kevin, R., Sachdev, S., Santiago, M., Stuart, J., Mack, J., Glass, M., McGregor, I., Connor, M., Kassiou, M. (2016). Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. ACS Chemical Neuroscience, 7(9), 1241-1254. [More Information]
• Hicks, C., Ramos, L., Dampney, B., Baracz, S., McGregor, I., Hunt, G. (2016). Regional c-Fos expression induced by peripheral oxytocin administration is prevented by the vasopressin 1A receptor antagonist SR49059. Brain Research Bulletin, 127, 208-218. [More Information]
• Grierson, A., McGregor, I., Naismith, S., Scott, J. (2016). The role of rumination in illness trajectories in youth: Linking trans-diagnostic processes with clinical staging models. Psychological Medicine, 46(12), 2467-2484. [More Information]

2015

• Allsop, D., Lintzeris, N., Copeland, J., Dunlop, A., McGregor, I. (2015). Cannabinoid Replacement Therapy (CRT): Nabiximols (Sativex) as a Novel Treatment for Cannabis Withdrawal. Clinical Pharmacology & Therapeutics, 97(6), 571-574. [More Information]
• Banister, S., Stuart, J., Kevin, R., Edington, A., Longworth, M., Wilkinson, S., Beinat, C., Buchanan, A., Hibbs, D., Glass, M., McGregor, I., Kassiou, M., et al (2015). Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience, 6(8), 1445-1458. [More Information]
• Elcombe, E., Lagopoulos, J., Duffy, S., Lewis, S., Norrie, L., McGregor, I., Naismith, S. (2015). Hippocampal Volume in Older Adults at Risk of Cognitive Decline: The Role of Sleep, Vascular Risk, and Depression. In Gwenn S. Smith (Eds.), Handbook of Depression in Alzheimer's Disease, (pp. 217-228). Amsterdam: IOS Press. [More Information]
• Husain, M., Calvo, R., Ellis, L., Li, J., Ospina Pinillos, L., Davenport, T., McGregor, I. (2015). NLG-based moderator response generator to support mental health. 33rd Annual CHI Conference on Human Factors in Computing Systems (CHI 2015), New York: Association for Computing Machinery (ACM). [More Information]
• Ramos, L., Hicks, C., Caminer, A., Goodwin, J., McGregor, I. (2015). Oxytocin and MDMA ("Ecstasy") enhance social reward in rats. Psychopharmacology, 232(14), 2631-2641. [More Information]
• Bowen, M., Peters, S., Absalom, N., Chebib, M., Neumann, I., McGregor, I. (2015). Oxytocin prevents ethanol actions at δ subunitcontaining GABAA receptors and attenuates ethanolinduced motor impairment in rats. Proceedings of the National Academy of Sciences of the United States of America, 112(10), 3104-3109. [More Information]
• Banister, S., Moir, M., Stuart, J., Kevin, R., Wood, K., Longworth, M., Wilkinson, S., Beinat, C., Buchanan, A., Glass, M., McGregor, I., Kassiou, M., et al (2015). Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 6(9), 1546-1559. [More Information]
• Banister, S., Stuart, J., Conroy, T., Longworth, M., Manohar, M., Beinat, C., Wilkinson, S., Kevin, R., Hibbs, D., Glass, M., McGregor, I., Kassiou, M., et al (2015). Structure-activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. Forensic Toxicology, 33(2), 355-366. [More Information]
• Allsop, D., Bartlett, D., Johnston, J., Helliwell, D., Winstock, A., McGregor, I., Lintzeris, N. (2015). The Effects of Lithium Carbonate Supplemented with Nitrazepam on Sleep Disturbance during Cannabis Abstinence. The Journal of Clinical Sleep Medicine, 11(10), 1153-1162. [More Information]
• McGregor, I., Carson, D., Guastella, A., Bowen, M. (2015). Pat: Treatment of Alcohol Use Disorders With Oxytocin and Other Agents Acting at Oxytocin Receptors. Patent No. 2010302945, 2010302945, 2482835, 9119805, 2482835. , , Germany, Ireland, Italy, Spain, Sweden, United Kingdom, Germany, Ireland, Italy, Spain, Sweden, United Kingdom.
• Hicks, C., Ramos, L., Reekie, T., Narlawar, R., Kassiou, M., McGregor, I. (2015). WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action. Psychopharmacology, 232, 2659-2667. [More Information]

2014

• Einfeld, S., Smith, E., McGregor, I., Steinbeck, K., Taffe, J., Rice, L., Horstead, S., Rogers, N., Redoblado Hodge, M., Guastella, A. (2014). A Double-Blind Randomized Controlled Trial of Oxytocin Nasal Spray in Prader Willi Syndrome. American Journal of Medical Genetics, Part A, 164A (9), 2232-2239. [More Information]
• Too, L., Ball, H., McGregor, I., Hunt, N. (2014). A novel automated test battery reveals enduring behavioural alterations and cognitive impairments in survivors of murine pneumococcal meningitis. Brain, Behavior, and Immunity, 35, 107-124. [More Information]
• Bowen, M., Hari Dass, S., Booth, J., Suraev, A., Vyas, A., McGregor, I. (2014). Active coping toward predatory stress is associated with lower corticosterone and progesterone plasma levels and decreased methylation in the medial amygdala vasopressin system. Hormones and Behavior, 66(3), 561-566. [More Information]
• Suraev, A., Bowen, M., Ali, S., Hicks, C., Ramos, L., McGregor, I. (2014). Adolescent exposure to oxytocin, but not the selective oxytocin receptor agonist TGOT, increases social behavior and plasma oxytocin in adulthood. Hormones and Behavior, 65(5), 488-496. [More Information]
• Hicks, C., Ramos, L., Reekie, T., Misagh, G., Narlawar, R., Kassiou, M., McGregor, I. (2014). Body temperature and cardiac changes induced by peripherally administered oxytocin, vaspressin and the non-peptide oxytocin receptor agonist WAY 267, 464: a biotelemetry study in rats. British Journal of Pharmacology, 171(11), 2868-2887. [More Information]
• Allsop, D., Dunlop, A., Sadler, C., Rivas, G., McGregor, I., Copeland, J. (2014). Changes in cigarette and alcohol use during cannabis abstinence. Drug and Alcohol Dependence, 138, 54-60. [More Information]
• Wong, A., Keats, K., Rooney, K., Hicks, C., Allsop, D., Arnold, J., McGregor, I. (2014). Fasting and exercise increase plasma cannabinoid levels in THC pre-treated rats: an examination of behavioural consequences. Psychopharmacology, 231(20), 3987-3996. [More Information]
• Ramos, L., Hicks, C., Caminer, A., McGregor, I. (2014). Inhaled vasopressin increases sociability and reduces body temperature and heart rate in rats. Psychoneuroendocrinology, 46, 46-51. [More Information]
• Too, L., Mitchell, A., Yau, B., Ball, H., McGregor, I., Hunt, N. (2014). Interleukin-18 deficiency and its long-term behavioural and cognitive impacts in a murine model of pneumococcal meningitis. Behavioural Brain Research, 263, 176-189. [More Information]
• Johnston, J., Lintzeris, N., Allsop, D., Suraev, A., Booth, J., Carson, D., Helliwell, D., Winstock, A., McGregor, I. (2014). Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting. Psychopharmacology, 231(24), 4623-4636. [More Information]
• Karanges, E., Stephenson, C., McGregor, I. (2014). Longitudinal trends in the dispensing of psychotropic medications in Australia from 2009-2012: Focus on children, adolescents and prescriber specialty. Australian and New Zealand Journal of Psychiatry, 48(10), 917-931. [More Information]
• Allsop, D., Copeland, J., Lintzeris, N., Dunlop, A., Montebello, M., Sadler, C., Rivas, G., Holland, R., Muhleisen, P., Norberg, M., Booth, J., McGregor, I. (2014). Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial. JAMA Psychiatry, 71(3), 281-291. [More Information]
• Ahmed, S., Kashem, M., Sarker, R., Ahmed, E., Hargreaves, G., McGregor, I. (2014). Neuroadaptations in the Striatal Proteome of the Rat Following Prolonged Excessive Sucrose Intake. Neurochemical Research, 39(5), 815-824. [More Information]
• Bowen, M., McGregor, I. (2014). Oxytocin and vasopressin modulate the social response to threat: a preclinical study. International Journal of Neuropsychopharmacology, 17, 1621-1633. [More Information]
• Barron, M., Werry, E., McGregor, I., Kassiou, M. (2014). P2X7 in Bipolar and Depressive Disorders. In Norbert Weiss, Alexandra Koschak (Eds.), Pathologies of Calcium Channels, (pp. 635-661). Berlin: Springer-Verlag. [More Information]
• Reekie, T., McGregor, I., Kassiou, M. (2014). Pyrazolo 1,4 diazepines as non-peptidic probes of the oxytocin and vasopressin receptors. Tetrahedron Letters, 55(33), 4568-4571. [More Information]
• van Nieuwenhuijzen, P., McGregor, I., Chebib, M., Hunt, G. (2014). Regional Fos-expression induced by γ-hydroxybutyrate (GHB): Comparison with γ-butyrolactone (GBL) and effects of co-administration of the GABAB antagonist SCH 50911 and putative GHB antagonist NCS-382. Neuroscience, 277, 700-715. [More Information]
• Wilkinson, S., Gunosewoyo, H., Barron, M., Boucher, A., McDonnell, M., Turner, P., Morrison, D., Bennett, M., McGregor, I., Rendina, L., Kassiou, M. (2014). The first CNS-active carborane: A novel P2X7 receptor antagonist with antidepressant activity. ACS Chemical Neuroscience, 5(5), 335-339. [More Information]
• Too, L., McQuillan, J., Ball, H., Kanai, M., Nakamura, T., Funakoshi, H., McGregor, I., Hunt, N. (2014). The kynurenine pathway contributes to long-term neuropsychological changes in experimental pneumococcal meningitis. Behavioural Brain Research, 270, 179-195. [More Information]
• Too, L., Ball, H., McGregor, I., Hunt, N. (2014). The pro-inflammatory cytokine interferon-gamma is an important driver of neuropathology and behavioural sequelae in experimental pneumococcal meningitis. Brain, Behavior, and Immunity, 40, 252-268. [More Information]

2013

• Carson, D., Guastella, A., Taylor, E., McGregor, I. (2013). A brief history of oxytocin and its role in modulating psychostimulant effects. Journal of Psychopharmacology, 27(3), 231-247. [More Information]
• Quintana, D., McGregor, I., Guastella, A., Malhi, G., Kemp, A. (2013). A Meta-Analysis on the Impact of Alcohol Dependence on Short-Term Resting-State Heart Rate Variability: Implications for Cardiovascular Risk. Alcoholism: Clinical and Experimental Research, 37(S1), E23-E29. [More Information]
• Ramos, L., Hicks, C., Kevin, R., Caminer, A., Narlawar, R., Kassiou, M., McGregor, I. (2013). Acute Prosocial Effects of Oxytocin and Vasopressin When Given Alone or in Combination with 3,4-Methylenedioxymethamphetamine in Rats: Involvement of the VI(A) Receptor. Neuropsychopharmacology, 38(11), 2249-2259. [More Information]
• Swift, W., Wong, A., Li, K., Arnold, J., McGregor, I. (2013). Analysis of cannabis seizures in NSW, Australia: Cannabis potency and cannabinoid profile. PloS One, 8(7), 1-9. [More Information]
• Bowen, M., Kevin, R., May, M., Staples, L., Hunt, G., McGregor, I. (2013). Defensive Aggregation (Huddling) in Rattus Norvegicus toward Predator Odor: Individual Differences, Social Buffering Effects and Neural Correlates. PloS One, 8(7), 1-15. [More Information]
• Bosanquet, D., MacDougall, H., Rogers, S., Starmer, G., McKetin, R., Blaszczynski, A., McGregor, I. (2013). Driving on ice: Impaired driving skills in current methamphetamine users. Psychopharmacology, 225, 161-172. [More Information]
• Wong, A., Montebello, M., Norberg, M., Rooney, K., Lintzeris, N., Bruno, R., Booth, J., Arnold, J., McGregor, I. (2013). Exercise increases plasma THC concentrations in regular cannabis users. Drug and Alcohol Dependence, 133(2), 763-767. [More Information]
• Hunt, G., McGregor, I., Malhi, G. (2013). Give me a hi-5! An additional version of the h-index. Australian and New Zealand Journal of Psychiatry, 47(12), 1119-1123. [More Information]
• Quintana, D., Guastella, A., McGregor, I., Hickie, I., Kemp, A. (2013). Heart rate variability predicts alcohol craving in alcohol dependent outpatients: Further evidence for HRV as a psychophysiological marker of self-regulation. Drug and Alcohol Dependence, 132(1-2), 395-398. [More Information]
• Motbey, C., Clemens, K., Apetz, N., Winstock, A., Ramsey, J., Li, K., Wyatt, N., Callaghan, P., Bowen, M., Cornish, J., McGregor, I. (2013). High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: Neural consequences and comparison with methamphetamine. Journal of Psychopharmacology, 27(9), 823-836. [More Information]
• Karanges, E., Kashem, M., Sarker, R., Ahmed, E., Ahmed, S., van Nieuwenhuijzen, P., Kemp, A., McGregor, I. (2013). Hippocampal protein expression is differentially affected by chronic paroxetine treatment in adolescent and adult rats: a possible mechanism of "paradoxical" antidepressant responses in young persons. Frontiers in Pharmacology, 4, 1-13. [More Information]
• Quintana, D., Guastella, A., McGregor, I., Hickie, I., Kemp, A. (2013). Moderate alcohol intake is related to increased heart rate variability in young adults: Implications for health and well-being. Psychophysiology, 50(12), 1202-1208. [More Information]
• Spencer, J., Darbyshire, K., Boucher, A., Kashem, M., Long, L., McGregor, I., Karl, T., Arnold, J. (2013). Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice. Frontiers in Cellular Neuroscience, 7, 1-13. [More Information]
• McGregor, I., Bowen, M. (2013). Oxytocin and addiction: recent preclinical advances and future clinical potential. In E. Choleris, D. W. Pfaff, & M. Kavaliers (Eds.), Oxytocin, Vasopressin and Related Peptides in the Regulation of Behavior, (pp. 270-287). Cambridge, UK: Cambridge University Press.
• Banister, S., Wilkinson, S., Longworth, M., Stuart, J., Apetz, N., English, K., Brooker, L., Goebel, C., Hibbs, D., Glass, M., McGregor, I., Kassiou, M., et al (2013). The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse. ACS Chemical Neuroscience, 4(7), 1081-1092. [More Information]
• Long, L., Chesworth, R., Huang, X., McGregor, I., Arnold, J., Karl, T. (2013). Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. International Journal of Neuropsychopharmacology, 16(1), 163-175. [More Information]
• Stephenson, C., Karanges, E., McGregor, I. (2013). Trends in the utilisation of psychotropic medications in Australia from 2000-2011. Australian and New Zealand Journal of Psychiatry, 47(1), 74-87. [More Information]

2012

• Bowen, M., Keats, K., Kendig, M., Cakic, V., Callaghan, P., McGregor, I. (2012). Aggregation in quads but not pairs of rats exposed to cat odor or bright light. Behavioural Processes, 90(3), 331-336. [More Information]
• Ahmed, E., Ahmed, S., Ukai, W., Matsumoto, I., Kemp, A., McGregor, I., Kashem, M. (2012). Antipsychotic Induced Alteration of Growth and Proteome of Rat Neural Stem Cells. Neurochemical Research, 37, 1649-1659. [More Information]
• McGregor, I., Bowen, M. (2012). Breaking the loop: Oxytocin as a potential treatment for drug addiction. Hormones and Behavior, 61(3), 331-339. [More Information]
• Long, L., Chesworth, R., Huang, X., Wong, A., Spiro, A., McGregor, I., Arnold, J., Karl, T. (2012). Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice. PloS One, 7(4), 1-11. [More Information]
• Kashem, M., Ahmed, S., Sarker, R., Ahmed, E., Hargreaves, G., McGregor, I. (2012). Long-term daily access to alcohol alters dopamine-related synthesis and signaling proteins in the rat striatum. Neurochemistry International, 61(8), 1280-1288. [More Information]
• Banister, S., Wilkinson, S., Connor, M., McGregor, I., Kassiou, M. (2012). Medicinal chemists breaking bad: The clandestine rational design of cannabimimetic indoles as drugs of abuse. The clandestine rational design of cannabimimetic indoles as drugs of abuse. Frontiers in medicinal chemistry, Australia: RACI.
• Motbey, C., Hunt, G., Bowen, M., Artiss, S., McGregor, I. (2012). Mephedrone (4-Methylmethcathinone, "Meow"): Acute Behavioural Effects and Distribution of Fos Expression in Adolescent Rats. Addiction Biology, 17(2), 409-422. [More Information]
• Motbey, C., Karanges, E., Li, K., Wilkinson, S., Winstock, A., Ramsay, J., Hicks, C., Kendig, M., Wyatt, N., Callaghan, P., McGregor, I. (2012). Mephedrone in adolescent rats: Residual memory impairment and acute but not lasting 5-HT depletion. PloS One, 7(9), 1-10. [More Information]
• Baracz, S., Rourke, P., Pardey, M., Hunt, G., McGregor, I., Cornish, J. (2012). Oxytocin directly administered into the nucleus accumbens core or subthalamic nucleus attenuates methamphetamine-induced conditioned place preference. Behavioural Brain Research, 228(1), 185-193. [More Information]
• Carson, D., Bosanquet, D., Carter, S., Pournajafi-Nazarloo, H., Blaszczynski, A., McGregor, I. (2012). Preliminary Evidence for Lowered Basal Cortisol in a Naturalistic Sample of Methamphetamine Polydrug Users. Experimental and Clinical Psychopharmacology, 20(6), 497-503. [More Information]
• Cornish, J., Hunt, G., Robins, L., McGregor, I. (2012). Regional c-Fos and FosB/δFosB expression associated with chronic methamphetamine self-administration and methamphetamine-seeking behavior in rats. Neuroscience, 206, 100-114. [More Information]
• May, M., Bowen, M., McGregor, I., Timberlake, W. (2012). Rubbings deposited by cats elicit defensive behavior in rats. Physiology and Behavior, 107(5), 711-718. [More Information]
• Wong, A., Gunasekaran, N., Hancock, D., Denyer, G., Meng, L., Radford, J., McGregor, I., Arnold, J. (2012). The major plant-derived cannabinoid 9-tetrahydrocannabinol promotes hypertrophy and macrophage infiltration in adipose tissue. Hormone And Metabolic Research, 44(2), 105-113. [More Information]
• Hicks, C., Jorgensen, W., Brown, C., Fardell, J., Koehbach, J., Gruber, C., Kassiou, M., Hunt, G., McGregor, I. (2012). The Nonpeptide Oxytocin Receptor Agonist WAY 267,464: Receptor-Binding Profile, Prosocial Effects and Distribution of c-Fos Expression in Adolescent Rats. Journal of Neuroendocrinology, 24(7), 1012-1029. [More Information]

2011

• Hunt, G., van Nieuwenhuijzen, P., Chan-Ling, T., McGregor, I. (2011). 'When an old rat smells a cat': a decline in defense-related, but not accessory olfactory, Fos expression in aged rats. Neurobiology of Aging, 32(4), 737-749. [More Information]
• Bowen, M., Carson, D., Spiro, A., Arnold, J., McGregor, I. (2011). Adolescent Oxytocin Exposure Causes Persistent Reductions in Anxiety and Alcohol Consumption and Enhances Sociability in Rats. PloS One, 6(11), e27237-1-e27237-11. [More Information]
• Karanges, E., McGregor, I. (2011). Antidepressants and adolescent brain development. Future Neurology, 6(6), 783-808. [More Information]
• Hargreaves, G., Wang, E., Lawrence, A., McGregor, I. (2011). Beer promotes high levels of alcohol intake in adolescent and adult alcohol-preferring rats. Alcohol, 45(5), 485-498. [More Information]
• Klein, C., Karanges, E., Spiro, A., Wong, A., Spencer, J., Huynh, T., Gunasekaran, N., Karl, T., Long, L., Huang, X., Arnold, J., McGregor, I., et al (2011). Cannabidiol potentiates D9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology, 218(2), 443-457. [More Information]
• Karanges, E., Li, K., Motbey, C., Callaghan, P., Katsifis, A., McGregor, I. (2011). Differential behavioural and neurochemical outcomes from chronic paroxetine treatment in adolescent and adult rats: a model of adverse antidepressant effects in human adolescents? International Journal of Neuropsychopharmacology, 14(4), 491-504. [More Information]
• Ferguson (Sokolic), L., Long, L., Hunt, G., Arnold, J., McGregor, I. (2011). Disruptive effects of the prototypical cannabinoid Delta9-tetrahydrocannabinol and the fatty acid amide inhibitor URB-597 on go/no-go auditory discrimination performance and olfactory reversal learning in rats. Behavioural Pharmacology, 22(3), 191-202. [More Information]
• Hunt, G., McGregor, I., Cornish, J., Callaghan, P. (2011). MDMA-induced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635. Brain Research Bulletin, 86, 65-73. [More Information]
• Kendig, M., Bowen, M., Kemp, A., McGregor, I. (2011). Predatory threat induces huddling in adolescent rats and residual changes in early adulthood suggestive of increased resilience. Behavioural Brain Research, 225(2), 405-414. [More Information]
• Boucher, A., Arnold, J., Hunt, G., Spiro, A., Spencer, J., Brown, C., McGregor, I., Bennett, M., Kassiou, M. (2011). Resilience and Reduced C-FOS Expression in P2X7 Receptor Knockout Mice Exposed to Repeated Forced Swim Test. Neuroscience, 189, 170-177. [More Information]
• Verty, A., Evetts, M., Crouch, G., McGregor, I., Stefanidis, A., Oldfield, B. (2011). The Cannabinoid Receptor Agonist THC Attenuates Weight Loss in a Rodent Model of Activity-Based Anorexia. Neuropsychopharmacology, 36, 1349-1358. [More Information]
• Boucher, A., Hunt, G., Micheau, J., Huang, X., McGregor, I., Karl, T., Arnold, J. (2011). The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. International Journal of Neuropsychopharmacology, 14(5), 631-643. [More Information]

2010

• van Nieuwenhuijzen, P., Kashem, M., Matsumoto, I., Hunt, G., McGregor, I. (2010). A long hangover from party drugs: Residual proteomic changes in the hippocampus of rats 8 weeks after gamma-hydroxybutyrate (GHB),3,4-methylenedioxymethamphetamine (MDMA) or their combination. Neurochemistry International, 56(8), 871-877. [More Information]
• Arnold, J., Dielenberg, R., McGregor, I. (2010). Cannabinoids increase conditioned ultrasonic vocalisations and cat odour avoidance in rats: Strain differences in drug-induced anxiety. Life Sciences, 87(17-18), 572-578. [More Information]
• Carson, D., Cornish, J., Guastella, A., Hunt, G., McGregor, I. (2010). Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, and relapse to methamphetamine-seeking behaviour in rats. Neuropharmacology, 58(1), 38-43. [More Information]
• van Nieuwenhuijzen, P., Long, L., Hunt, G., Arnold, J., McGregor, I. (2010). Residual social, memory and oxytocin-related changes in rats following repeated exposure to gamma-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. Psychopharmacology, 212(4), 663-674. [More Information]
• Carson, D., Hunt, G., Guastella, A., Barber, L., Cornish, J., Arnold, J., Boucher, A., McGregor, I. (2010). Systemically administered oxytocin decreases methamphetamine activation of the subthalamic nucleus and accumbens core and stimulates oxytocinergic neurons in the hypothalamus. Addiction Biology, 15(4), 448-463. [More Information]
• Thompson, M., Callaghan, P., McGregor, I. (2010). The Pharmacology of MDMA (Ecstasy). In Degenhardt L. & Hall W. (Eds.), The Health and Psychological Effects of "Ecstasy" (MDMA) Use, (pp. 47-80). Randwick, NSW: National Drug and Alcohol Research Centre.

2009

• Long, L., Chesworth, R., Huang, X., McGregor, I., Arnold, J., Karl, T. (2009). A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. International Journal of Neuropsychopharmacology, 13 (2010)(7), 861-876. [More Information]
• Kashem, M., Sarker, R., Des Etages, H., Machaalani, R., King, N., McGregor, I., Matsumoto, I. (2009). Comparative proteomics in the corpus callosal sub-regions of postmortem human brain. Neurochemistry International, 55(7), 483-490. [More Information]
• Kashem, M., Des Etages, H., Kopitar-Jerala, N., McGregor, I., Matsumoto, I. (2009). Differential protein expression in the corpus callosum (body) of human alcoholic brain. Journal of Neurochemistry, 110(2), 486-495. [More Information]
• Kashem, M., Ummehany, R., Ukai, W., Hashimoto, E., Saito, T., McGregor, I., Matsumoto, I. (2009). Effects of typical (haloperidol) and atypical (risperidone) antipsychotic agents on protein expression in rat neural stem cells. Neurochemistry International, 55(7), 558-565. [More Information]
• Hargreaves, G., Monds, L., Gunasekaran, N., Dawson, B., McGregor, I. (2009). Intermittent access to beer promotes binge-like drinking in adolescent but not adult Wistar rats. Alcohol, 43, 305-314. [More Information]
• Verty, A., Boon, W., Mallett, P., McGregor, I., Oldfield, B. (2009). Involvement of hypothalamic peptides in the anorectic action of the CB1 receptor antagonist rimonabant (SR 141716). European Journal of Neuroscience, 29(11), 2207-2216. [More Information]
• Staples, L., McGregor, I., Hunt, G. (2009). Long-lasting FosB/delta-FosB immunoreactivity in the rat brain after repeated cat odor exposure. Neuroscience Letters, 462(2), 157-161. [More Information]
• Thompson, M., Hunt, G., McGregor, I. (2009). Neural correlates of MDMA ("Ecstasy")-induced social interaction in rats. Social Neuroscience, 4(1), 60-72. [More Information]
• Hargreaves, G., Quinn, H., Kashem, M., Matsumoto, I., McGregor, I. (2009). Proteomic Analysis Demonstrates Adolescent Vulnerability to Lasting Hippocampal Changes Following Chronic Alcohol Consumption. Alcoholism: Clinical and Experimental Research, 33(1), 86-94. [More Information]
• Gunasekaran, N., Long, L., Dawson, B., Hansen, G., Richardson, D., Li, K., Arnold, J., McGregor, I. (2009). Reintoxication: the release of fat-stored delta-9-tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure. British Journal of Pharmacology, 158(5), 1330-1337. [More Information]
• van Nieuwenhuijzen, P., McGregor, I., Hunt, G. (2009). The distribution of gamma-hydroxybutyrate-induced Fos expression in rat brain: Comparison with baclofen. Neuroscience, 158(2), 441-455. [More Information]
• van Nieuwenhuijzen, P., Li, K., Hunt, G., McGregor, I. (2009). Weekly gamma-hydroxybutyrate exposure sensitizes locomotor hyperactivity to low-dose 3,4-methylenedioxymethamphetamine in rats. Neuropsychobiology, 60(3-4), 195-203. [More Information]

2008

• Rutten, K., Reneerkensa, O., Hamers, H., Sik, A., McGregor, I., Prickaerts, J., Blokland, A. (2008). Automated scoring of novel object recognition in rats. Journal of Neuroscience Methods, 171, 72-77. [More Information]
• Staples, L., McGregor, I., Apfelbach, R., Hunt, G. (2008). Cat odor, but not trimethylthiazoline (fox odor), activates accessory olfactory and defense-related brain regions in rats. Neuroscience, 151, 937-947. [More Information]
• McGregor, I., Callaghan, P., Hunt, G. (2008). From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use? British Journal of Pharmacology, 154, 358-368. [More Information]
• Cornish, J., Clemens, K., Thompson, M., Callaghan, P., Dawson, B., McGregor, I. (2008). High ambient temperature increases intravenous methamphetamine self-administration on fixed and progressive ratio schedules in rats. Journal of Psychopharmacology, 22(1), 100-110. [More Information]
• Iwazaki, T., McGregor, I., Matsumoto, I. (2008). Protein expression profile in the amygdala of rats with methamphetamine-induced behavioral sensitization. Neuroscience Letters, 435(2), 113-119. [More Information]
• Staples, L., Hunt, G., van Nieuwenhuijzen, P., McGregor, I. (2008). Rats discriminate individual cats by their odor: Possible involvement of the accessory olfactory system. Neuroscience and Biobehavioral Reviews, 32(7), 1209-1217. [More Information]
• Thompson, M., Callaghan, P., Hunt, G., McGregor, I. (2008). Reduced sensitivity to MDMA-induced facilitation of social behaviour in MDMA pre-exposed rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32(4), 1013-1021. [More Information]

2007

• Thompson, M., Callaghan, P., Hunt, G., Cornish, J., McGregor, I. (2007). A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy"). Neuroscience, 146(2), 509-514. [More Information]
• Quinn, H., Matsumoto, I., Callaghan, P., Long, L., Arnold, J., Gunasekaran, N., Thompson, M., Dawson, B., Mallet, P., Kashem, M., Matsuda-Matsumoto, H., Iwazaki, T., McGregor, I. (2007). Adolescent rats find repeated delta-9-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology, 33(5), 1113-1126. [More Information]
• Ferguson (Sokolic), L., Laing, D., McGregor, I. (2007). Asymmetric suppression of components in binary aldehyde mixtures: Behavioral studies in the laboratory rat. Chemical Senses, 32(2), 191-199. [More Information]
• Ferguson (Sokolic), L., McGregor, I. (2007). Benzodiazepines impair the acquisition and reversal of olfactory go/no-go discriminations in rats. Behavioral Neuroscience, 121(3), 527-534. [More Information]
• McGregor, I., Arnold, J. (2007). Cannabis reward: biased towards the fairer sex? British Journal of Pharmacology, 152(5), 562-564. [More Information]
• Boucher, A., Hunt, G., Karl, T., Micheau, J., McGregor, I., Arnold, J. (2007). Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience, 149(4), 861-870. [More Information]
• Hargreaves, G., Hunt, G., Cornish, J., McGregor, I. (2007). High ambient temperature increases 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy")-induced Fos expression in a region-specific manner. Neuroscience, 145(2), 764-774. [More Information]
• Chan-Ling, T., Hughes, S., Baxter, L., Rosinova, E., McGregor, I., Morcos, Y., van Nieuwenhuijzen, P., Hu, P. (2007). Inflammation and breakdown of the blood-retinal barrier during "physiological aging" in the rat retina: A model for CNS aging. Microcirculation, 14(1), 63-76. [More Information]
• Clemens, K., McGregor, I., Hunt, G., Cornish, J. (2007). MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research. Drug and Alcohol Review, 26(1), 9-15. [More Information]
• Iwazaki, T., McGregor, I., Matsumoto, I. (2007). Protein expression profile in the striatum of rats with methamphetamine-induced behavioral sensitization. Proteomics, 7(7), 1131-1139. [More Information]
• Clemens, K., Cornish, J., Hunt, G., McGregor, I. (2007). Repeated weekly exposure to MDMA, methamphetamine or their combination: Long-term behavioural and neurochemical effects in rats. Drug and Alcohol Dependence, 86(2-3), 183-190. [More Information]
• Creelman, A., Thominiaux, C., Chauveau, F., Fulton, R., Kuhnast, B., Henderson, D., Boutin, H., Selleri, S., McGregor, I., Hantraye, P., Kassiou, M., et al (2007). Synthesis and evaluation of the translocator protein (18kDa) (TSPO) ligand (11C)DPA0715 in rat and non-human primate. 17th International Symposium on Radiopharmaceutical Sciences. John Wiley & Sons.
• Hargreaves, G., McGregor, I. (2007). Topiramate moderately reduces the motivation to consume alcohol and has a marked antidepressant effect in rats. Alcoholism: Clinical and Experimental Research, 31(11), 1900-1907. [More Information]

2006

• Staples, L., McGregor, I. (2006). Defensive responses of Wistar and Sprague-Dawley rats to cat odour and TMT. Behavioural Brain Research, 172(2), 351-354. [More Information]
• Siviy, S., Harrison, K., McGregor, I. (2006). Fear, risk assessment, and playfulness in the juvenile rat. Behavioral Neuroscience, 120(1), 49-59. [More Information]
• Clemens, K., Cornish, J., Hunt, G., McGregor, I. (2006). Intravenous methamphetamine self-administration in rats: Effects of intravenous or intraperitoneal MDMA co-administration. Pharmacology, Biochemistry and Behavior, 85, 454-463. [More Information]
• Iwazaki, T., McGregor, I., Matsumoto, I. (2006). Protein expression profile in the striatum of acute methamphetamine-treated rats. Brain Research, 1097, 19-25. [More Information]
• O'Shea, M., McGregor, I., Mallet, P. (2006). Repeated cannabinoid exposure during perinatal, adolescent, or early adult ages produces similar long-lasting deficits in object recognition and reduced social interaction in rats. Journal of Psychopharmacology, 20(5), 611-621. [More Information]

2005

• Hargreaves, G., McGregor, I., Sachdev, P. (2005). Chronic repetitive transcranial magnetic stimulation is antidepressant but not anxiolytic in rat models of anxiety and depression. Psychiatry Research, 137(1-2), 113-121. [More Information]
• Young, J., McGregor, I., Mallet, P. (2005). Co-administration of THC and MDMA ('Ecstasy') synergistically disrupts memory in rats. Neuropsychopharmacology, 30(8), 1475-1482. [More Information]
• Cornish, J., Lontos, J., Clemens, K., McGregor, I. (2005). Cocaine and heroin ('speedball') self-administration: the involvement of nucleus accumbens dopamine and mu-opiate, but not delta-opiate receptors. Psychopharmacology, 180(1), 21-32. [More Information]
• McGregor, I., Adamec, R., Canteras, N., Blanchard, R., Blanchard, C. (2005). Defensive behavior. Neuroscience and Biobehavioral Reviews, 29(8), 1121-1122. [More Information]
• McGregor, I., Dam, K., Mallet, P., Gallate, J. (2005). Delta(9)-THC reinstates beer- and sucrose-seeking behaviour in abstinent rats: Comparison with midazolam, food deprivation and predator odour. Alcohol and Alcoholism, 40(1), 35-45. [More Information]
• Clemens, K., Cornish, J., Li, K., Hunt, G., McGregor, I. (2005). MDMA ('Ecstasy') and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats. Neuropharmacology, 49(2), 195-207. [More Information]
• McGregor, I., Clemens, K., Cornish, J., Thompson, M., He, S., Clarke, S., Kohn, M., Gordon, E. (2005). MDMA, methamphetamine and their combination: Comparison of long-term behavioural and neural effects in rats. Behavioural Pharmacology, 16, S11-S11.
• Staples, L., Hunt, G., Cornish, J., McGregor, I. (2005). Neural activation during cat odor-induced conditioned fear and 'trial 2' fear in rats. Neuroscience and Biobehavioral Reviews, 29(8), 1265-1277. [More Information]
• Verty, A., McGregor, I., Mallet, P. (2005). Paraventricular hypothalamic CB1 cannabinoid receptors are involved in the feeding stimulatory effects of Delta(9)-tetrahydrocannabinol. Neuropharmacology, 49(8), 1101-1109. [More Information]
• Singh, M., McGregor, I., Mallet, P. (2005). Perinatal exposure to Delta(9)-tetrahydrocannabinol alters heroin-induced place conditioning and Fos-immunoreactivity. Neuropsychopharmacology, 31(1), 1-12. [More Information]
• Singh, M., McGregor, I., Mallet, P. (2005). Repeated exposure to Delta(9)-tetrahydrocannabinol alters heroin-induced locomotor sensitisation and Fos-immunoreactivity. Neuropharmacology, 49(8), 1189-1200. [More Information]
• Morley, K., Arnold, J., McGregor, I. (2005). Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 29(5), 648-657. [More Information]
• Apfelbach, R., Blanchard, C., Blanchard, R., Hayes, R., McGregor, I. (2005). The effects of predator odors in mammalian prey species: A review of field and laboratory studies. Neuroscience and Biobehavioral Reviews, 29(8), 1123-1144. [More Information]
• Fendt, M., Endres, T., Lowry, C., Apfelbach, R., McGregor, I. (2005). TMT-induced autonomic and behavioral changes and the neural basis of its processing. Neuroscience and Biobehavioral Reviews, 29(8), 1145-1156. [More Information]

2004

• Morley, K., Li, K., Hunt, G., Mallet, P., McGregor, I. (2004). Cannabinoids Prevent The Acute Hyperthermia And Partially Protect Against The 5-Ht Depleting Effects Of Mdma ('Ecstasy') In Rats. Neuropharmacology, 46(7), 954-965. [More Information]
• Thompson, M., Li, K., Clemens, K., Gurtman, C., Hunt, G., Cornish, J., McGregor, I. (2004). Chronic Fluoxetine Treatment Partly Attenuates The Long-Term Anxiety And Depressive Symptoms Induced By Mdma ('Ecstasy') In Rats. Neuropsychopharmacology, 29(4), 694-704. [More Information]
• Gallate, J., McGregor, I., Mallet, P. (2004). Combined Low Dose Treatment With Opioid And Cannabinoid Receptor Antagonists Synergistically Reduces The Motivation To Consume Alcohol In Rats. Psychopharmacology, 173(1-2), 210-216. [More Information]
• McGregor, I., Verty, A., Mallet, P. (2004). Consumption Of High Carbohydrate, High Fat, And Normal Chow Is Equally Suppressed By A Cannabinoid Receptor Antagonist In Non-Deprived Rats. Neuroscience Letters, 354(3), 217-220. [More Information]
• Ball, H., MacDougall, H., McGregor, I., Hunt, N. (2004). Cyclooxygenase-2 In The Pathogenesis Of Murine Cerebral Malaria. The Journal of Infectious Diseases, 189(4), 751-758. [More Information]
• Verty, A., McFarlane, J., McGregor, I., Mallet, P. (2004). Evidence For An Interaction Between Cb1 Cannabinoid And Melanocortin MCR-4 Receptors In Regulating Food Intake. Endocrinology, 145(7), 3224-3231. [More Information]
• Verty, A., McFarlane, J., McGregor, I., Mallet, P. (2004). Evidence For An Interaction Between Cb1 Cannabinoid And Oxytocin Receptors In Food And Water Intake. Neuropharmacology, 47(4), 593-603. [More Information]
• Clemens, K., van Nieuwenhuijzen, P., Li, K., Cornish, J., Hunt, G., McGregor, I. (2004). Mdma ('Ecstasy'), Methamphetamine And Their Combination: Long-Term Changes In Social Interaction And Neurochemistry In The Rat. Psychopharmacology, 173(38445), 318-325. [More Information]
• McGregor, I., Hargreaves, G., Apfelbach, R., Hunt, G. (2004). Neural Correlates Of Cat Odor-Induced Anxiety In Rats: Region-Specific Effects Of The Benzodiazepine Midazolam. Journal of Neuroscience, 24(17), 4134-4144. [More Information]
• Morley, K., Cornish, J., Li, K., McGregor, I. (2004). Preexposure To Mdma ("Ecstasy") Delays Acquisition But Facilitates Mdma-Induced Reinstatement Of Amphetamine Self-Administration Behavior In Rats. Pharmacology, Biochemistry and Behavior, 79(2), 331-342. [More Information]
• Li, K., Thompson, M., McGregor, I. (2004). Rapid Quantitation Of Fluoxetine And Norfluoxetine In Serum By Micro-Disc Solid-Phase Extraction With High-Performance Liquid Chromatography-Ultraviolet Absorbance Detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 804(2), 319-326. [More Information]
• McGregor, I., Gallate, J. (2004). Rats On The Grog: Novel Pharmacotherapies For Alcohol Craving,. Addictive Behaviors, 29(7), 1341-1357. [More Information]
• Verty, A., McGregor, I., Mallet, P. (2004). The Doparnine Receptor Antagonist Sch 23390 Attenuates Feeding Induced By Delta(9)-Tetrahydrocannobinol. Brain Research, 1020 (38384), 188-195. [More Information]

2003

• Cornish, J., Shahnawaz, Z., Thompson, M., Wong, S., Morley, K., Hunt, G., McGregor, I. (2003). Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. European Journal of Pharmacology, 482(1-3), 339-341. [More Information]
• McGregor, I., Clemens, K., Van Der Plasse, G., Li, K., Hunt, G., Chen, F., Lawrence, A. (2003). Increased Anxiety 3 Months after Brief Exposure to MDMA ('Ecstasy') in Rats: Association with Altered 5-HT Transporter and Receptor Density. Neuropsychopharmacology, 28, 1472-1484. [More Information]
• McGregor, I., Gurtman, C., Morley, K., Clemens, K., Li, K., Blokland, A., Cornish, J., Hunt, G. (2003). Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology, 168(4), 465-474. [More Information]
• Norwood, C., Cornish, J., Mallet, P., McGregor, I. (2003). Pre-exposure to the cannabinoid receptor agonist CP 55,940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. European Journal of Pharmacology, 465(1-2), 105-114. [More Information]
• Allen, K., McGregor, I., Hunt, G., Singh, M., Mallet, P. (2003). Regional differences in nalaxone modulation of Delta 9 - THC induced Fos expression in rat brain. Neuropharmacology, 44(2), 264-274. [More Information]
• Verty, A., Singh, M., McGregor, I., Mallet, P. (2003). The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology, 168(3), 314-323. [More Information]
• Gallate, J., Morley, K., Ambermoon, P., McGregor, I. (2003). The consequences of beer consumption in rats: acute anxiolytic and ataxic effects and withdrawal-induced anxiety. Psychopharmacology, 166(1), 51-60. [More Information]

2002

• Hunt, G., McGregor, I. (2002). Contrasting effects of dopamine antagonists and frequency reduction on Fos expression induced by lateral hypothalamic stimulation. Behavioural Brain Research, 132(2), 187-201. [More Information]
• Gurtman, C., Morley, K., Li, K., Hunt, G., McGregor, I. (2002). Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. European Journal of Pharmacology, 446(1-3), 89-96. [More Information]
• McGregor, I., Schrama, L., Ambermoon, P., Dielenberg, R. (2002). Not all 'predator odours' are equal: cat odur but not 2,4,5 trimrthylthiazoline (TMT; fox odour) elicits specific defensive behaviours in rats. Behavioural Brain Research, 130(1-2), 1-16. [More Information]
• Green, R., McGregor, I. (2002). On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA. Psychopharmacology, 162(4), 448-450.

2001

• Dielenberg, R., Hunt, G., McGregor, I. (2001). 'When a rat smells a cat': The distribution of fos immunoreactivity in rat brain following exposure to a predatory odor. Neuroscience, 104, 1085-1097.
• Dielenberg, R., McGregor, I. (2001). Defensive behvior in rats towards predatory odors: a review. Neuroscience and Biobehavioral Reviews, 25, 597-609.
• Arnold, J., Hunt, G., McGregor, I. (2001). Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rat. Life Sciences, 70, 97-108.
• Morley, K., Gallate, J., Hunt, G., McGregor, I., Mallet, P. (2001). Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("Ecstasy"). European Journal of Pharmacology, 433(1), 91-99. [More Information]
• Dielenberg, R., McGregor, I., Carrive, P. (2001). The cardiovascular and behavioral response to cat odor in rats: unconditioned and conditioned effects. Brain Research, 897, 228-237.
• Arnold, J., Topple, A., Hunt, G., McGregor, I., Mallet, P. (2001). The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain. Brain Research, 921, 240-255.